{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T04:47:29Z","timestamp":1772945249453,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12185-025-04117-7","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T09:53:08Z","timestamp":1764669188000},"page":"394-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct immunophenotypic profiles of circulating tumor plasma cells in MGUS and smoldering multiple myeloma"],"prefix":"10.1007","volume":"123","author":[{"given":"Atsushi","family":"Uehara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminari","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Oura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Toho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikako","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8669-9865","authenticated-orcid":false,"given":"Kosei","family":"Matsue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"3","key":"4117_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241\u20139.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"4117_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1182\/blood-2021-148617","volume":"138","author":"S Thorsteinsdottir","year":"2021","unstructured":"Thorsteinsdottir S, Gislason GK, Aspelund T, R\u00f6gnvaldsson S, Oskarsson JTT, Petursdottir I, et al. Prevalence of smoldering multiple myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study. Blood. 2021;138(Supplement 1):151\u2013151.","journal-title":"Blood"},{"issue":"25","key":"4117_CR3","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582\u201390.","journal-title":"N Engl J Med"},{"issue":"27","key":"4117_CR4","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.21.01365","volume":"40","author":"J-J Garc\u00e9s","year":"2022","unstructured":"Garc\u00e9s J-J, Cedena M-T, Puig N, Burgos L, Perez JJ, Cordon L, et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol. 2022;40(27):3151\u201361.","journal-title":"J Clin Oncol"},{"issue":"27","key":"4117_CR5","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1200\/JCO.22.01040","volume":"40","author":"R Chakraborty","year":"2022","unstructured":"Chakraborty R, Lentzsch S. Circulating tumor cell burden as a component of staging in multiple myeloma: ready for prime time? J Clin Oncol. 2022;40(27):3099\u2013102.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4117_CR6","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","volume":"106","author":"GS Nowakowski","year":"2005","unstructured":"Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276\u20139.","journal-title":"Blood"},{"issue":"10","key":"4117_CR7","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/leu.2014.98","volume":"28","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 2014;28(10):2060\u20135.","journal-title":"Leukemia"},{"issue":"4","key":"4117_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.63","volume":"8","author":"PR Tembhare","year":"2024","unstructured":"Tembhare PR, Sriram H, Khanka T, Gawai S, Bagal B, Ghogale SG, et al. Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant. HemaSphere. 2024;8(4):e63.","journal-title":"HemaSphere"},{"issue":"24","key":"4117_CR9","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1200\/JCO.2005.03.159","volume":"23","author":"S Kumar","year":"2005","unstructured":"Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol. 2005;23(24):5668\u201374.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4117_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","volume":"8","author":"L Sanoja-Flores","year":"2018","unstructured":"Sanoja-Flores L, Flores-Montero J, Garc\u00e9s JJ, Paiva B, Puig N, Garc\u00eda-Mateo A, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8(12):117.","journal-title":"Blood Cancer J"},{"issue":"3","key":"4117_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/leu.2012.237","volume":"27","author":"G Bianchi","year":"2013","unstructured":"Bianchi G, Kyle RA, Larson DR, Witzig TE, Kumar S, Dispenzieri A, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27(3):680\u20135.","journal-title":"Leukemia"},{"issue":"1","key":"4117_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/leu.2016.205","volume":"31","author":"WI Gonsalves","year":"2017","unstructured":"Gonsalves WI, Rajkumar SV, Dispenzieri A, Dingli D, Timm MM, Morice WG, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017;31(1):130\u20135.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"4117_CR13","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1182\/blood-2023-188538","volume":"142","author":"E Kastritis","year":"2023","unstructured":"Kastritis E, Malandrakis P, Kostopoulos IV, Ntanasis-Stathopoulos I, Solia I, Fotiou D, et al. Circulating tumor cells by next generation flow cytometry may be a new prognostic biomarkers among patients with asymptomatic monoclonal gammopathies. Blood. 2023;142(Supplement 1):3401\u20133401.","journal-title":"Blood"},{"issue":"1","key":"4117_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1365-2141.1997.72653.x","volume":"97","author":"AC Rawstron","year":"1997","unstructured":"Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97(1):46\u201355.","journal-title":"Br J Haematol"},{"issue":"22","key":"4117_CR15","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","volume":"122","author":"B Paiva","year":"2013","unstructured":"Paiva B, Paino T, Sayagues J-M, Garayoa M, San-Segundo L, Mart\u00edn M, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591\u20138.","journal-title":"Blood"},{"issue":"8","key":"4117_CR16","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41375-018-0030-3","volume":"32","author":"A Lakshman","year":"2018","unstructured":"Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, et al. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 2018;32(8):1811\u20135.","journal-title":"Leukemia"},{"issue":"12","key":"4117_CR17","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1038\/s41375-018-0202-1","volume":"32","author":"M Merz","year":"2018","unstructured":"Merz M, Hielscher T, Hoffmann K, Seckinger A, Hose D, Raab MS, et al. Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance. Leukemia. 2018;32(12):2717\u20139.","journal-title":"Leukemia"},{"issue":"34","key":"4117_CR18","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","volume":"31","author":"K Neben","year":"2013","unstructured":"Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013;31(34):4325\u201332.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4117_CR19","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/leu.2013.86","volume":"27","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27(8):1738\u201344.","journal-title":"Leukemia"},{"issue":"2","key":"4117_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00277-014-2211-0","volume":"94","author":"G An","year":"2015","unstructured":"An G, Qin X, Acharya C, Xu Y, Deng S, Shi L, et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol. 2015;94(2):257\u201364.","journal-title":"Ann Hematol"},{"issue":"12","key":"4117_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.117","volume":"6","author":"R Chakraborty","year":"2016","unstructured":"Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, et al. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J. 2016;6(12):e512.","journal-title":"Blood Cancer J"},{"issue":"3","key":"4117_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ajh.25709","volume":"95","author":"WI Gonsalves","year":"2020","unstructured":"Gonsalves WI, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am J Hematol. 2020;95(3):310\u20135.","journal-title":"Am J Hematol"},{"issue":"12","key":"4117_CR23","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"10","key":"4117_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"M-V Mateos","year":"2020","unstructured":"Mateos M-V, Kumar S, Dimopoulos MA, Gonz\u00e1lez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.","journal-title":"Blood Cancer J"},{"issue":"1","key":"4117_CR25","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1038\/s41598-019-39631-2","volume":"9","author":"A Blum","year":"2019","unstructured":"Blum A, Haussmann K, Streitz M, Schlickeiser S, Tietze-Buerger C, Blau IW, et al. Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma. Sci Rep. 2019;9(1):2922.","journal-title":"Sci Rep"},{"issue":"1","key":"4117_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/cyto.b.21228","volume":"90","author":"M Arroz","year":"2016","unstructured":"Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31\u20139.","journal-title":"Cytometry B Clin Cytom"},{"issue":"8","key":"4117_CR27","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Guti\u00e9rrez NC, Liebisch P, O\u2019Connor S, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97(8):1272\u20137.","journal-title":"Haematologica"},{"issue":"5","key":"4117_CR28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1182\/blood.2024026028","volume":"145","author":"D Ikeda","year":"2025","unstructured":"Ikeda D, Aikawa S, Misono C, Oura M, Fujii F, Sakuma H, et al. Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma. Blood. 2025;145(5):526\u201332.","journal-title":"Blood"},{"issue":"1","key":"4117_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41408-023-00944-1","volume":"13","author":"O P\u00e9rez-Escurza","year":"2023","unstructured":"P\u00e9rez-Escurza O, Flores-Montero J, \u00d3skarsson J\u00de, Sanoja-Flores L, Del Pozo J, Lecrevisse Q, et al. Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study. Blood Cancer J. 2023;13(1):182.","journal-title":"Blood Cancer J"},{"issue":"7","key":"4117_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.bbmt.2013.04.025","volume":"19","author":"M Korthals","year":"2013","unstructured":"Korthals M, Sehnke N, Kronenwett R, Schroeder T, Strapatsas T, Kobbe G, et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma. Biol Blood Marrow Transplant. 2013;19(7):1109\u201315.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4117_CR31","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai Y-T, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840\u20138.","journal-title":"J Immunol"},{"issue":"2","key":"4117_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10585-007-9125-3","volume":"25","author":"RD Sanderson","year":"2008","unstructured":"Sanderson RD, Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis. 2008;25(2):149\u201359.","journal-title":"Clin Exp Metastasis"},{"issue":"3","key":"4117_CR33","first-page":"226","volume":"34","author":"F Ceran","year":"2017","unstructured":"Ceran F, Falay M, Da\u011fda\u015f S, \u00d6zet G. The assessment of CD56 and CD117 expressions at the time of the diagnosis in multiple myeloma patients. Turk J Hematol. 2017;34(3):226\u201332.","journal-title":"Turk J Hematol"},{"issue":"S1","key":"4117_CR34","first-page":"S47","volume":"78","author":"M Perez-Andres","year":"2010","unstructured":"Perez-Andres M, Paiva B, Nieto WG, Caraux A, Schmitz A, Almeida J, et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom. 2010;78(S1):S47-60.","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"4117_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3324\/haematol.2010.031872","volume":"96","author":"M Schmidt-Hieber","year":"2011","unstructured":"Schmidt-Hieber M, P\u00e9rez-Andr\u00e9s M, Paiva B, Flores-Montero J, Perez JJ, Gutierrez NC, et al. CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features. Haematologica. 2011;96(2):328\u201332.","journal-title":"Haematologica"},{"issue":"12","key":"4117_CR36","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1182\/blood-2004-12-4700","volume":"105","author":"N Robillard","year":"2005","unstructured":"Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood. 2005;105(12):4845\u20138.","journal-title":"Blood"},{"issue":"8","key":"4117_CR37","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/sj.leu.2403823","volume":"19","author":"S Kumar","year":"2005","unstructured":"Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia. 2005;19(8):1466\u201370.","journal-title":"Leukemia"},{"issue":"14","key":"4117_CR38","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1182\/blood.2020009088","volume":"137","author":"T Sewastianik","year":"2021","unstructured":"Sewastianik T, Straubhaar JR, Zhao J-J, Samur MK, Adler K, Tanton HE, et al. miR-15a\/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021;137(14):1905\u201319.","journal-title":"Blood"},{"issue":"1","key":"4117_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/0008-5472.BCD-19-0068","volume":"1","author":"M Chesi","year":"2020","unstructured":"Chesi M, Stein CK, Garbitt VM, Sharik ME, Asmann YW, Bergsagel M, et al. Monosomic loss of MIR15A\/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. Blood Cancer Discov. 2020;1(1):68\u201381.","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"4117_CR40","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","volume":"34","author":"J-J Garc\u00e9s","year":"2020","unstructured":"Garc\u00e9s J-J, Simicek M, Vicari M, Brozova L, Burgos L, Bezdekova R, et al. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Leukemia. 2020;34(2):589\u2013603.","journal-title":"Leukemia"},{"issue":"24","key":"4117_CR41","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","volume":"119","author":"AK Azab","year":"2012","unstructured":"Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012;119(24):5782\u201394.","journal-title":"Blood"},{"issue":"1","key":"4117_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.12223","volume":"161","author":"L Billecke","year":"2013","unstructured":"Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161(1):87\u201394.","journal-title":"Br J Haematol"},{"issue":"9","key":"4117_CR43","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/sj.bmt.1705982","volume":"41","author":"MC Minnema","year":"2008","unstructured":"Minnema MC, van de Donk NWCJ, Zweegman S, Hegenbart U, Schonland S, Raymakers R, et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant. 2008;41(9):779\u201384.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"4117_CR44","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/sj.bmt.1704713","volume":"34","author":"R Zeiser","year":"2004","unstructured":"Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant. 2004;34(12):1057\u201365.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"4117_CR45","first-page":"1207","volume":"110","author":"M Toho","year":"2025","unstructured":"Toho M, Ikeda D, Aikawa S, Misono C, Oura M, Fujii F, et al. Serum B-cell maturation antigen could be a simple and accurate biomarker to identify and prognosticate monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Haematologica. 2025;110(5):1207\u201310.","journal-title":"Haematologica"},{"issue":"1","key":"4117_CR46","doi-asserted-by":"publisher","first-page":"11218","DOI":"10.1038\/s41598-021-89761-9","volume":"11","author":"T Yoroidaka","year":"2021","unstructured":"Yoroidaka T, Narita K, Takamatsu H, Fujisawa M, Nakao S, Matsue K. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods. Sci Rep. 2021;11(1):11218.","journal-title":"Sci Rep"},{"issue":"9","key":"4117_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.83","volume":"7","author":"M Binder","year":"2017","unstructured":"Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017;7(9):e600.","journal-title":"Blood Cancer J"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04117-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04117-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04117-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:01:51Z","timestamp":1772892111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04117-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4117"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04117-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.M. received research funding from AstraZeneca for an unrelated project. The other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}